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Background: The oncogenic ether-à-go-go-1 potassium channel (EAG1) activity and expression are necessary for
cell cycle progression and tumorigenesis. The active vitamin D metabolite, calcitriol, and astemizole, a promising
antineoplastic drug, target EAG1 by inhibiting its expression and blocking ion currents, respectively. We have
previously shown a synergistic antiproliferative effect of calcitriol and astemizole in breast cancer cells in vitro, but
the effect of this dual therapy in vivo has not been studied.
Methods: In the present study, we explored the combined antineoplastic effect of both drugs in vivo using mice
xenografted with the human breast cancer cell line T-47D and a primary breast cancer-derived cell culture (MBCDF).
Tumor-bearing athymic female mice were treated with oral astemizole (50 mg/kg/day) and/or intraperitoneal
injections of calcitriol (0.03 μg/g body weight twice a week) during 3 weeks. Tumor sizes were measured thrice
weekly. For mechanistic insights, we studied EAG1 expression by qPCR and Western blot. The expression of Ki-67
and the relative tumor volume were used as indicators of therapeutic efficacy.
Results: Compared to untreated controls, astemizole and calcitriol significantly reduced, while the coadministration
of both drugs further suppressed, tumor growth (P < 0.05). In addition, the combined therapy significantly
downregulated tumoral EAG1 and Ki-67 expression.
Conclusions: The concomitant administration of calcitriol and astemizole inhibited tumor growth more efficiently
than each drug alone, which may be explained by the blocking of EAG1. These results provide the bases for further
studies aimed at testing EAG1-dual targeting in breast cancer tumors expressing both EAG1 and the vitamin D
receptor.
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Breast cancer is the most frequently diagnosed malig-
nant neoplasia and the leading cause of cancer death
among women worldwide [1]. One out of eight women
will develop breast cancer during their lifetime. The
standard medical treatment for breast cancer besides
surgery and radiotherapy include cytotoxic chemother-
apy, which targets rapidly dividing cells. However, this
clinical approach is highly toxic, affects normal cells and
causes a wide array of side effects. In the last decades,
substantial changes in cancer therapy have been made.
Among them, new anticancer drugs designed to
recognize specific features in cancer cells are being
produced. These drugs, created on the basis of their
targeted mechanism of action, are expected to be more
efficient with less toxicity. Approximately 80% of all
breast cancers are susceptible for hormonal or antibody-
based targeted therapy, based on the presence and/or
abundance of the estrogen receptor alpha (ERα), proges-
terone receptor (PR) and/or the human epidermal
growth factor receptor 2 (HER2). It is well known that
absence of ERα, PR and HER2 precludes targeted ther-
apies to these cell markers and often results in poorer
outcomes [2]. Therefore, identification of new molecular
targets expressed in breast tumors is needed. The ether
à-go-go-1 potassium channel (EAG1) became an onco-
logical target soon after the discovery of its involvement
in cell proliferation and apoptosis [3-6]. EAG1 promotes
oncogenesis and tumor progression, and its pharmaco-
logical inhibition reduces tumor development [4,6,7].
Moreover, EAG1 is upregulated by cancer-associated
factors such as estrogens and the human papilloma virus
[8]. Interestingly, a substantial proportion of breast tu-
mors including ERα-negative and triple-negative breast
cancers express EAG1 [5,9]. In this regard, the progres-
sion of breast cancer cells through the early G1 phase
has been shown to be dependent on the activation of
EAG1 channels [10-12]. Previously, our laboratory
showed that EAG1 expression and the rate of cell prolif-
eration are inhibited in breast and cervical cancer cells
by calcitriol, the active vitamin D metabolite [9,13]. Cal-
citriol is an important endogenous as well as exogenous
anticancer hormone. The antiproliferative effects of
calcitriol have been extensively demonstrated in many
cancerous cell types, most of them involving the ligand-
activated vitamin D receptor (VDR) [14,15]. Since the
induction of cell cycle arrest and apoptosis by calcitriol
depends on the expression of the VDR, this protein rep-
resents a good therapeutic target in treating cancer [16].
Previous in vitro studies by our group have shown that
astemizole, a non-selective EAG1 blocker, synergized
with calcitriol to inhibit breast cancer cell proliferation
by modifying EAG1 gene expression and possibly its ac-
tivity as well [17]. In addition, these studies also showedthat astemizole upregulates VDR expression and down-
regulates the calcitriol-degrading enzyme CYP24A1;
thus, increasing calcitriol bioactivity while decreasing its
degradation. Taken together these observations and the
fact that the VDR and EAG1 are expressed in 90% and
85%; respectively, of breast cancer tumors [18-21], we
hypothesized that a combined treatment targeting these
two proteins in vivo could result in an improved thera-
peutic benefit for breast cancer management, including
those tumors not treatable by hormonal therapy. In the
present study we investigated the effects of calcitriol
alone or in combination with astemizole on tumor
growth in an in vivo preclinical model using athymic
mice xenografted with two different human breast can-
cer cell lines: T-47D (ERα, VDR and EAG1 positive) and
a ductal infiltrating carcinoma breast cancer-derived
primary cell culture (MBCDF, ERα negative, VDR and
EAG1 positive) [22]. These two cell lines were selected
because they represent different types of breast tumors
based on the expression of the ERα. In addition, both
express the selected therapeutic targets and both were
tumorigenic. Herein, we show for the first time that the
concomitant in vivo administration of calcitriol and




Calcitriol (1,25-dihydroxycholecalciferol) was kindly do-
nated from Hoffmann-La Roche Ltd (Basel, Switzerland).
Astemizole was acquired as a pediatric suspension from
the local pharmacy (Astesen® Senosiain Laboratories).
Breast cancer cell culture
The MBCDF primary breast cancer cell culture was
generated from a biopsy obtained from a radical mastec-
tomy performed on a patient with an infiltrating ductal
carcinoma stage IV. The protocol was approved by the
Human Research Ethics Committee from the Instituto
Nacional de Ciencias Médicas y Nutrición Salvador
Zubirán (INCMNSZ) in Mexico City (Ref 1549, BQO-
008-06/9-1) [22] and written informed consent was
obtained from the patient. Cells were maintained in
humidified atmosphere with 5% CO2 at 37°C in RPMI-
1640 medium supplemented with 100 units/mL penicillin
plus 100 μg/mL streptomycin and 5% heat-inactivated
fetal bovine serum. The established human breast cancer
cell line T-47D was also used in this study (ATCC,
Manassas, VA) and was maintained following indications
from the supplier.
Immunocytochemistry
Cultured cells were grown on glass coverslips and
fixated in ethanol 96%. Antigen retrieval was done by
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blocked with immunodetector peroxidase blocker (Bio
SB, Santa Bárbara CA, USA). For EAG1, additional
blocking was performed using background Sniper (Biocare
Medical, CA, USA). The following primary antibodies
were incubated for 2 hours: Anti- ERα (1:250, Bio SB),
anti-VDR (1:100, Santa Cruz Biotechnology Inc, CA,
USA) and anti-EAG1 (1:300, Novus Biologicals CO,
USA). After washing, the slides were sequentially incu-
bated with immuno-Detector Biotin-Link and immuno-
Detector HRP label (Bio SB) during 10 minutes each.
Staining was completed with diaminobenzidine (DAB)
and slides were counterstained with hematoxylin.
Induction of tumors in athymic mice
Studies involving mice were performed according to the
rules and regulations of the Official Mexican Norm 062-
ZOO-1999. The study was approved by the Institutional
Committee for the care and use of laboratory animals
(protocol number BRE-31-10-13-1, CINVA 31) of the
INCMNSZ, where mice were housed in the animal facil-
ity. Athymic female BALB/c homozygous, inbred Crl:NU
(NCr)-Foxn1nu nude mice (~6 weeks of age) were kept
in ventilated cages (34 air changes hourly) with bedding
of aspen wood-shavings, controlled temperature, humid-
ity and 12:12 light:dark periods. Sterilized water and feed
(standard PMI 5053 feed) were given ad libitum. Appro-
priate animal observations were made in order to
minimize/alleviate any potential pain, distress, or dis-
comfort by choosing the earliest endpoint compatible
with the scientific objectives of this work. Tumors were
induced by subcutaneous injection of MBCDF or T-47D
cells (2.0 x 106) in 0.1 mL of sterile saline solution into
the upper part of the posterior limb of each mouse.
Therapeutic protocol
When the tumors reached a palpable mass (~3 mm),
mice were randomly divided in 4 groups and received ei-
ther: vehicle (i.p. ethanol, 1.8 μL/100 μL of sterile saline
solution), calcitriol (i.p. 0.03 μg/g of body weight every
Tuesday and Thursday), astemizole (p.o. 50 mg/kg/day),
or calcitriol + astemizole during 3 weeks. At least 15
mice were included in each group. The dosage of the
drugs and the intermittent calcitriol administration
regimen were based on published observations [23,24].
The suspension of astemizole was diluted in the drinking
water of mice. Each mouse is estimated to drink 5–7 mL
of water per day, which was taken into consideration to
achieve as close as possible the dose of astemizole [25].
This supplemented water was changed every day.
Weight loss was used as a parameter for toxicity; thus,
mice were weighed three times per week to determine
any toxic effect of the drugs. Tumor sizes were also
measured thrice weekly throughout the experiment.Tumors were measured with a caliper always by the
same person. Tumor volume was calculated using the
standard formula (length x width2)/2, where length is
the largest dimension and width the smallest dimension
perpendicular to the length. Fold increase from initial
volume was calculated for each single tumor by dividing
the tumor volume on day 21 by that on day 0 (which
corresponded to the tumor volume in the first day of
treatment, and was set to one).
Imunohistochemistry
Tumoral tissue was collected upon termination of the
study and immediately fixed in 10% aqueous formalde-
hyde followed by routine paraffin embedding proce-
dures. Two-micrometer sections were cut, dewaxed in
xylene and re-hydrated with descending concentrations
of ethanol. Antigen retrieval was done by autoclaving in
ImmunoDNA Retriever Citrate (Bio SB). Slides were
blocked with PolyDetector Peroxidase Blocker (Bio SB)
and then incubated in the presence of a monoclonal
anti-Ki-67 antibody (1:100, Bio SB). Next, the slides were
incubated with Immuno-Detector HRP label (Bio SB)
and staining was completed with DAB. After identifying
areas with the most intensive staining, counting of Ki-
67- positive cells was done in three different fields per
tumor slide in pictures taken with the 20 X objective.
Herein, to reduce the subjectivity, three independent ob-
servers participated in the counting procedure of Ki-67
positive cells. Afterwards, average number of stained
cells was calculated for each group.
Real Time PCR (qPCR)
Total RNA was extracted by homogenizing the tissue in
the presence of Trizol reagent (Life Technologies, Carlbad,
USA). Two μg of total RNA were reverse-transcribed and
resulting cDNAs were used for the qPCR. The reverse
transcription system and the TaqMan Master reagents
were from Roche (Roche Applied Science, IN, USA).
Amplifications were carried out in the LightCycler® 2.0
from Roche, according to the following protocol: activa-
tion of Taq DNA polymerase and DNA denaturation at
95°C for 10 min, followed by 45 amplification cycles con-
sisting of 10 s at 95°C, 30 s at 60°C, and 1 s at 72°C. Gene
expression of the housekeeping genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) or β-actin was used
as internal control for T-47D and MBCDF, respectively.
Primers sequences were as follows: human EAG1 (hEAG1)
[GenBank:AF078741.1]: cct gga ggt gat cca aga tg/cca aac
acg tct cct ttt cc; GAPDH [GenBank:AF261085.1]: agc cac
atc gct gag aca c/gcc caa tac gac caa atc c and β-actin
[GenBank:NM_001101.3]: cca aac cgc gag aag atg a/cca gag
gcg tac agg gat ag. Corresponding probe numbers from the
universal probe library (Roche) were: 49, 60, and 64 for
hEAG1, GAPDH and β-actin respectively. A sample of
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this tissue (mEAG1) [GenBank:NM_001038607.1]. For this
we used: acg ctt ttg aga acg tgg at/ccg cac aac ttt cag aga
act; and the housekeeping gene mus musculus ribosomal
protein L32 (mL32) [GenBank:NM_172086.2]: gct gcc atc
tgt ttt acg g / tga ctg gtg cct gat gaa ct with corresponding
probes No. 66 and 46, respectively. In all cases the expres-
sion of the gene of interest was normalized against the
housekeeping gene and control values were arbitrarily set
to one.
Determination of serum total calcium
Blood samples from three mice in each experimental
group were obtained by cardiac puncture under
anesthesia, causing exsanguination until the animal
death. Total serum calcium concentration was deter-
mined by indirect potentiometry using a calcium select-
ive electrode in conjunction with a sodium reference
electrode (Synchrom Clinical System CX5 PRO, Beck-
man Coulter Inc., Fullerton, CA, USA).
Western blot
A piece of the excised tumors was homogenized with
RIPA buffer (9.1 mM dibasic sodium phosphate, 1.7 mM
monobasic sodium phosphate, 150 mM NaCl, 1% Nonidet
P-40, 0.1% SDS, pH 7.4) in the presence of a protease
inhibitor cocktail (Roche) using a Polytron homogenizer
(BioSpec Products, Inc.). Thirty micrograms of total tissue
lysates were separated on 10% SDS-PAGE, transferred to
Immobilon-P PVDF membranes (Millipore, Billerica, MA)
and blocked with 5% non-fat milk in PBS-Tween.
Membranes were incubated with respective antibodies atFigure 1 T-47D and MBCDF cell lines express VDR and EAG1. The cell
biomarkers for the targeted therapy. Cells were incubated in the presence
negative control (C-) and further processed as described under Materials an
Representative pictures are shown (40 X).appropriate dilutions: anti-EAG1 (Novus Biologicals CO,
1:300) and anti-GAPDH (Millipore, Temecula, CA,
1:10,000). For visualization, membranes were incubated
with respective horseradish peroxidase-conjugated sec-
ondary antibodies (1:10,000) and were processed with the
ECL + Plus Western blotting detection system (GE-
Healthcare, UK). Densitometric analysis of resulting bands
was performed by using ImageJ software (NIH, USA).
Statistical analysis
Statistical differences for dose–response assays were
determined by One-Way ANOVA followed by Holm-
Sidak for pair-wise comparisons (SigmaStat, Jandel
Scientific). Differences were considered statistically
significant at P < 0.05.
Results
Cell characterization
The cell lines MBCDF and T-47D were representative of
different breast cancer subtypes, based on the differential
expression of ERα. Whereas MBCDF and T-47D were
negative and positive for ERα, respectively, (data not
shown), both cell lines expressed VDR and EAG1
(Figure 1, brown staining).
Analysis of the tumor volume and Ki-67 expression
Two groups of nude mice were xenografted subcutaneously
either with MBCDF or T-47D tumorigenic breast cancer
cells and then randomly assigned to the different treat-
ments. The tumor volume analysis showed that calcitriol
and astemizole significantly reduced tumor growth per se
in both groups of mice (MBCDF and T-47D) compared tolines used in this study T-47D (A-C) and MBCDF (D-F) express both
of anti-VDR (A, D), anti-EAG1 (B, E) or without first antibody (C, F) as
d Methods. Positive immunoreactivity is shown in brown staining.
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further slowed tumor progression (Figure 2). Accordingly,
as shown in Figure 3, the percentage of Ki-67-positive
tumor cells was significantly lower in mice treated either
with astemizole or calcitriol alone compared to control
mice, and it was even lower in tumors from mice treated
with both drugs simultaneously.
The combined treatment with calcitriol and astemizole
downregulated EAG1 expression in the tumor tissue
Since previous studies showed that one of the mechanisms
involved in calcitriol anticancer effects in breast cancerFigure 2 The combined therapy slows the growth of tumors more eff
xenografted subcutaneously in nude mice. Treatment started after a palpab
3 weeks. A) Fold increase from initial volume was calculated for each tu
calcitriol (C), astemizole (A), combined therapy (CA). Black bars = MBCDF
each group, **P < 0.05 vs calcitriol alone. n ≥ 15 mice in each group. B, C
treatment with vehicle, calcitriol, astemizole and the combination of bowas its ability to inhibit EAG1 expression [9,17], we ex-
plored whether this process could also be taking place in
our in vivo model. As shown in Figure 4, calcitriol per se
significantly downregulated tumor EAG1 gene expression,
which was further reduced when calcitriol and astemizole
were administrated simultaneously. Next, we examined
whether tumor EAG1 protein levels were also affected by
the treatments. For this, EAG1 protein levels were evalu-
ated by Western blots of proteins extracted from tumors
derived from T-47D cells (Figure 5). As depicted, two
distinct bands were detected in the cell homogenates, with
an electrophoretic mobility corresponding to ∼ 110 and ∼iciently than each drug individually. MBCDF and T-47D cells were
le mass was evident (initial volume) and was administered during
mor by dividing the volume on day 21/initial volume. Vehicle (Vh);
; white bars = T-47D. Mean ± standard error. *P < 0.05 vs vehicle in
, D and E) Representative pictures depicting tumor final size after
th drugs, respectively.
Figure 3 Ki-67 was expressed by less tumoral cells in mice with combined therapy compared to monotherapy. Ki-67-positive cells in the
tumors were counted in slides from the groups of mice treated with: vehicle (Vh), calcitriol (C), astemizole (A) or their combination (CA). Upper
panel: Representative pictures of T-47D tumors from mice treated with the different drugs, showing immunohistochemistry studies of Ki-67
(nuclear, brown staining). Inset shows negative control in the absence of first antibody. All pictures are 20 X. Lower panel: Graphical representation of
positive Ki-67 cells in immunohistochemistry slides (%). Black bars =MBCDF; white bars = T-47D. After identifying areas with the most intensive staining,
counting of total cells was done in three different fields per tumor slide and the percentage of Ki-67- positive cells was calculated. Results are expressed
as the mean ± standard error. * P < 0.05 vs vehicle in each group. **P < 0.05 vs each drug alone.
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differential glycosylation patterns of asparagines at posi-
tions 388 and 406 of EAG1, as described elsewhere [26].
As shown in Figures 5B and C, the treatments reduced
significantly EAG1 protein expression when compared to
mice treated with vehicle. An unexpected finding was theeffect of astemizole by itself on EAG1 mRNA and protein
expression (Figures 4 and 5).
Interestingly, neither pharmacological agent alone or
combined modified EAG1 gene expression in a tissue that
normally expresses this ion channel, such as the brain.
The relative expression of EAG1 mRNA in the brains of
Figure 4 The combined treatment with calcitriol and astemizole downregulated EAG1 gene expression in the tumoral tissue.
The gene expression of tumoral EAG1 was assessed by RT-qPCR and normalized against the corresponding housekeeping gene. Values for
controls were arbitrarily set to one. Black bars = MBCDF; white bars = T-47D. *P < 0.05 vs. control in each group; n ≥ 15. Results are expressed
as the mean ± standard error.
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animals was: 0.090 ± 0.024, 0.095 ± 0.023, 0.103 ± 0.024
and 0.095 ± 0.016, respectively; n ≥ 5; P = 0.746.
Effects of calcitriol/astemizole treatment on serum levels
of total calcium and body weight
Calcium serum levels and body weight were used as pa-
rameters to evaluate specific calcitriol side effects. Mean
serum total calcium levels were not affected by the treat-
ments since calcemia was not significantly different
among groups (P = 0.06). However, the group that re-
ceived the combined regimen of calcitriol plus astemi-
zole had the highest serum calcium concentration
(Table 1). On the other hand, the final body weights
were not significantly different among the treated and
control groups (Table 1, P = 0.09), further indicating the
lack of relevant adverse side effects of the drugs used
herein at the doses tested, upon these two variables.
In addition, mice treated with astemizole showed a
healthy and soft skin, while the calcitriol-treated mice
showed mild dry skin.
Discussion
For a patient tailored anticancer therapy, the identifica-
tion of potential targets in tumor tissue is paramount to
predict therapeutic efficiency. Indeed, new antineoplastic
drugs are expected to be less toxic to the patient and more
tissue- and target-specific. Although some molecular
subgroups of breast cancer are beneficed from a targeted
therapy, the most aggressive tumors still lack molecular
targets, representing a clinical challenge. Among the newly
recognized therapeutic targets in oncology, EAG1 stands
as a promising candidate, considering its involvement inoncogenesis and tumor growth [27]. Other important
therapeutic target is the VDR; which is required to medi-
ate calcitriol antineoplastic effects, such as the repression
of EAG1 gene expression [9,13,28,29]. Therefore, drugs
that target the VDR and EAG1 represent novel approaches
to fight against breast cancer. Interestingly, both EAG1
and the VDR are expressed in most breast tumors, inde-
pendently of their general molecular signature [18-21].
Considering the latter, we designed a combined targeted
therapy directed to these biomarkers in vivo, based on the
rationale of a dual blocking of EAG1 with the purpose to
restrain its tumorigenic ability and consequently, tumor
progression. For this, we used astemizole and calcitriol to
inhibit EAG1 activity and gene expression; respectively, in
order to completely obstruct EAG1 functionality. The de-
sign of the study was conceived to be tested in a murine
model xenografted with two human breast cancer cell
lines expressing both EAG1 and the VDR. Tumor growth
reduction together with Ki-67 expression as proliferation
marker, were used as biological endpoints representing
therapeutic benefit. Taking into consideration these end-
points, the results showed that the combined regimen was
significantly more efficient to produce antitumor effects
than when either of the agents was tested alone. In
addition, calcitriol significantly inhibited tumoral EAG1
mRNA and protein expression, an effect that was further
increased by the co-administration with astemizole, show-
ing for the first time the in vivo inhibition of this oncogenic
potassium channel by these drugs in breast tumors.
Interestingly, the expression of EAG1 was also inhib-
ited by astemizole, in a similar manner as observed pre-
viously in vitro [17]. This could probably be explained
by astemizole blocking EAG1 channels located also in
Figure 5 Less tumor EAG1 protein expression was found in mice treated with the combined treatment. A) Representative Western blot
of EAG1 expression showing two different T-47D tumors per treatment. The mice bearing palpable tumors received vehicle (Vh); calcitriol (C),
astemizole (A) or the combination of both drugs (CA) for 3 weeks. Tumors were excised, homogenized and 30 μg of total protein were loaded
per lane. Two immunoreactive bands of ~110 kDa and 130 kDa (indicated by arrows) were detected. B) and C) represent the quantification of
the 130 kDa and 110 kDa bands, respectively. The expression of each of the two species of EAG1 was normalized against GAPDH optical density
(O.D) and results are shown as the mean ± standard deviation of EAG1 relative O.D of four different tumors from each treatment. *P < 0.05 vs. Vh.
Vehicle was given an arbitrary value of 1.
Table 1 Total calcium in mice serum and final body weights
Group Control Calcitriol Astemizole C + A
Total calcium (mg/dL) 9.8 ± 0.2 9.4 ± 0.7 10.0 ± 0.2 10.7 ± 0.6
Mean final body weight (g) 22.0 ± 2.0 21.4 ± 2.0 22.6 ± 2.8 21.0 ± 2.6
For calcium: data are expressed as the mean ± S.D., n = 3. The mean final body weight was calculated including both T-47D and MBCDF inoculated mice and are
presented as the mean ± S.D., n ≥ 24.
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to affect gene expression [30].
Besides the double inhibition of EAG1 by the com-
bined treatment, additional individual antiproliferative
effects of astemizole and calcitriol might also be taking
place, such as long-term blocking of histamine H1-
receptors, induction of apoptosis or the modification of
EAG1 activity and/or glycosylation patterns, which de-
serve to be further investigated.
Since calcitriol bioavailability and activity are potenti-
ated by astemizole [17], its effects on calcium serum
levels should be considered and avoided to prevent hy-
percalcemia, as an undesirable side effect. In this study,
only the combined therapy was accompanied by a mild
increase in serum calcium levels, which probably re-
sulted from improved calcitriol bioactivity. In addition,
no changes in the mean body weights between the
experimental and control groups were observed, and the
histopathological analysis of the lungs of treated animals
by a specialized pathologist did not show any signs of
toxicity, suggesting that the doses of calcitriol and aste-
mizole, as used in this study, were well tolerated. These
data suggested that the combined dosing regimen herein
reported could potentially be tested in patients with
breast cancer as an adjuvant therapy, with relative low
adverse side effects. Alternatively, dietary vitamin D in-
stead of calcitriol could be used since it is a safe, eco-
nomical and easily available nutritional agent, that has
proven to be equivalent to calcitriol in exerting antican-
cer effects in a preclinical model of breast cancer [31].
On the other hand, many different compounds may be
used to target EAG1; however, for the purposes of this
study we chose astemizole, given its well-known in vitro
and in vivo antiproliferative effects on tumor cells
through blocking ion currents [11,17,23,32]. In addition,
astemizole offers other advantages, such as the fact that
it is a low-priced drug currently prescribed for treatment
of simple allergic conditions or malaria in some coun-
tries and particularly because it does not cross the
blood–brain barrier [33]. Regarding this, the observation
that neither astemizole nor calcitriol modified the
expression of EAG1 in the brains of the treated mice, as
they did in breast cancer, was of particular importance
since normal brain cells express EAG1. This observation
may rule out alterations on the physiological role of
EAG1 at the level of the central nervous system.
Overall, our results confirm previous in vitro findings
[9,17] and support earlier studies showing EAG1 as a
promising target for the tailored treatment of human
tumors [21]. As previously suggested, reevaluation of
astemizole as an antineoplastic drug is needed [6].
In summary, in this study using an in vivo preclinical
animal model of breast cancer, the combined administra-
tion of calcitriol with astemizole improved significantlytheir individual therapeutic efficiency in terms of tumor
growth inhibition. This effect could be explained by the
dual inhibitory effect on EAG1 and increased calcitriol
bioactivity. Since both astemizole and calcitriol inhibit
EAG1 activity and expression, respectively, patients bear-
ing EAG1 and VDR-positive solid or metastatic tumors
may benefit from this EAG1 double blocking strategy.
Conclusions
The simultaneous administration of calcitriol and aste-
mizole to mice xenografted with human breast cancer
cells reduced tumor growth more efficiently than either
drug alone. The mechanistic explanation for these results
includes the inhibition of EAG1 expression, providing sci-
entific bases to test the combined therapy in future clinical
trials. The effect of the combined treatment was effective
in both types of tumors (ER negative and ER positive), as
seen in MBCDF and T-47D-xenografts, further supporting
the potential use of this therapeutic approach in breast
tumors that represent a clinical challenge, such as triple
negative and those resistant to endocrine therapy. Some of
the limitations of this study include the lack of serum
calcitriol quantification and the analysis of tumoral
VDR and CYP24A1 expression, which deserve to be
further investigated.
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